Analysts expect Oruka Therapeutics, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Oruka Therapeutics, Inc. to report earnings per share of -0.54 for Q2 26, against a range of -0.59 to -0.49. The most recent reported quarter, Q1 26, came in at -0.48, a 18.6% beat against the -0.59 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.76 | -1.46 | -0.49 | -0.40 | -0.46 | -0.55 | -0.45 | -0.48 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -0.38 | -0.68 | -0.49 | -0.43 | -0.50 | -0.56 | -0.53 | -0.49 | -0.51 | -0.50 | -0.56 | -0.52 | -0.59 | -0.43 | -0.76 | |||||||||||
| Low Estimate | - | -0.46 | -0.74 | -0.55 | -0.49 | -0.60 | -0.66 | -0.65 | -0.59 | -0.57 | -0.58 | -0.68 | -0.58 | -0.65 | -0.47 | -0.90 | |||||||||||
| Consensus Estimate | - | -0.42 | -0.71 | -0.52 | -0.46 | -0.55 | -0.61 | -0.59 | -0.54 | -0.54 | -0.54 | -0.62 | -0.55 | -0.62 | -0.45 | -0.83 |